Clinical Trial Update: Universal CAR-T Cell Injection Targeting CD19/BCMA in Patients With Inflammatory Bowel Disease [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial evaluating a universal CAR-T cell therapy targeting CD19 and BCMA for moderate-to-severe ulcerative colitis and Crohn's disease, currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• Universal CAR-T cell therapy targeting CD19 and BCMA (CAR-T cell therapy targeting CD19 and BCMA)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Moderate-to-severe Ulcerative Colitis, Crohn's Disease (CD) | EARLY_Phase 1 | Status: NOT_YET_RECRUITING